A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Exclusion criteria

• . Any previous CLL specific treatment.
• . Failure to fully recover adequately from prior surgical procedures at the discretion of the investigator. Patients who receive a major surgery within 28 days prior to the first dose of the study drug or who receive a minor surgery (excluding biopsy) within 14 days prior to the initiation of the study.
• . Presence of significant cardiovascular disease within 6 months prior to study entry.
• . A history of significant kidney, neurological, psychiatric, pulmonary, endocrine, metabolic, immune, cardiovascular, or liver disease, which will have an adverse effect on the patient if he/she participates in the study, at the discretion of the investigator.
• . Patients who require warfarin or other anticoagulants or active hemorrhage occur within 2 months before study entry.
• . Known to have hypersensitivity to the drug ingredient or its analogues.
• . Pregnant or lactating female patients and patients who are expected to become pregnant during the study period or within 3 months after the last dose.
• . Patients who have history of other active malignant tumor other than CLL/SLL within 3 years before study entry.